Streetbeat News

Stock Prices

CLAR

Clarus shares are trading lower after the company reported worse-than-expected Q2 financial results.

Portfolio Pulse from Benzinga Newsdesk

August 02, 2024 | 1:14 pm

CC

Chemours shares are trading lower after the company reported mixed Q2 financial results and issued weak Q3 net sales guidance.

Portfolio Pulse from Benzinga Newsdesk

August 02, 2024 | 1:09 pm

TEAM

Atlassian Corporation (NASDAQ:TEAM) reported better-than-expected Q4 earnings, with EPS of 66 cents beating the estimate of 60 cents and sales of $1.131 billion surpassing the $1.130 billion estimate. Despite positive results, the stock fell 1.9% to $173.24. Analysts revised their price targets: Baird downgraded to Neutral with a target of $175, Goldman Sachs upgraded to Buy with a target of $230, and Truist Securities maintained Hold but cut the target to $160.

Portfolio Pulse from Avi Kapoor

August 02, 2024 | 1:05 pm

CLSK

CleanSpark Inc. (NASDAQ: CLSK) released its July 2024 Bitcoin mining update, reporting 494 Bitcoin mined and a 567% YoY increase in treasury. The company expanded into Wyoming and Tennessee, securing power agreements and increasing its hashrate.

Portfolio Pulse from Benzinga Newsdesk

August 02, 2024 | 1:03 pm

NVDA

Elliott Management has stated that Nvidia is in a 'bubble' and that AI is 'overhyped'. This could lead to short-term volatility in Nvidia's stock price as investors react to these claims.

Portfolio Pulse from Benzinga Newsdesk

August 02, 2024 | 1:02 pm

W

JPMorgan analyst Christopher Horvers recommends buying Wayfair (NYSE:W) stock despite recent dips due to macroeconomic factors. He maintains an Overweight rating with a revised price target of $63 by December 2024, down from $80. Horvers believes Wayfair's long-term potential remains strong, citing market share gains and strategic initiatives.

Portfolio Pulse from Surbhi Jain

August 02, 2024 | 1:02 pm

AMLX

Amylyx Pharmaceuticals has received Orphan Drug Designation from the European Commission for its drug AMX0035, aimed at treating Wolfram Syndrome. The company expects topline data from its Phase 2 HELIOS trial in Fall 2024.

Portfolio Pulse from Benzinga Newsdesk

August 02, 2024 | 1:01 pm

PCTY

10 analysts have provided mixed opinions on Paylocity Holding (NASDAQ:PCTY) over the past quarter, with a range of ratings from bullish to indifferent. The average 12-month price target has decreased by 9.63% to $173.7. Recent analyst actions include several downgrades in price targets, reflecting cautious sentiment.

Portfolio Pulse from Benzinga Insights

August 02, 2024 | 1:00 pm

ARKG

ARKK

MRNA

Cathie Wood's Ark Invest purchased over $19 million worth of Moderna shares after the stock plunged 21% due to reduced revenue guidance. Moderna cited a competitive respiratory vaccine market and weak COVID-19 vaccine sales in Europe as reasons for the guidance cut. Ark's ETFs, ARKK and ARKG, bought 202,991 shares of Moderna, aligning with their strategy of buying on weakness.

Portfolio Pulse from Shanthi Rexaline

August 02, 2024 | 1:00 pm

NCPLW

Trading halt status was updated at 9:00:00 AM ET, with a quotation resumption announced. The news and resumption times are provided.

Portfolio Pulse from Benzinga Newsdesk

August 02, 2024 | 1:00 pm